We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Parexel, a global clinical research organisation (CRO), announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund (EQT Private Equity) and the private equity business within Goldman Sachs Asset Management ...